Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
GoodRx Holdings Inc Market Cap
From what 10 stock analysts predict, the share price for GoodRx Holdings Inc (GDRX) might increase by 12.39% in the next year. This is based on a 12-month average estimation for GDRX. Price targets go from $4.50 to $12.00. The majority of stock analysts believe GDRX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
GoodRx Holdings Inc has a total of 10 Wall St Analyst ratings. There are 3 buy ratings, 6 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that GoodRx Holdings Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| daniel grosslight Citi | Buy | $8.0 | maintained | Feb 12, 2024 |
| charles rhyee TD Cowen | Buy | $12.0 | maintained | Jan 30, 2024 |
| doug anmuth J.P. Morgan | Hold | $7.0 | maintained | Jan 23, 2024 |
| lisa gill J.P. Morgan | Hold | $7.0 | maintained | Jan 23, 2024 |
| eric sheridan Goldman Sachs | Hold | $6.5 | maintained | Jan 19, 2024 |
| allen lutz Bank of America Securities | Sell | $4.5 | reiterated | Jan 19, 2024 |
| sean dodge RBC Capital | Hold | $7.0 | maintained | Jan 16, 2024 |
| jailendra singh Truist Financial | Hold | $7.5 | maintained | Jan 12, 2024 |
| stan berenshteyn Wells Fargo | Hold | $6.0 | maintained | Jan 10, 2024 |
| stephanie davis Barclays | Buy | $8.0 | initiatedcoverage | Jan 2, 2024 |
| scott schoenhaus KeyBanc | Hold | None | rated | Dec 13, 2023 |
| george hill Deutsche Bank | Hold | $7.0 | maintained | Nov 10, 2023 |
| craig hettenbach Morgan Stanley | Hold | $5.5 | maintained | Nov 10, 2023 |
| robert simmons, cfa D.A. Davidson | Buy | $5.5 | reiterated | Nov 9, 2023 |
| glen santangelo Jefferies | Buy | $7.0 | maintained | Aug 25, 2023 |
| vikram kesavabhotla Robert W. Baird | Hold | $8.0 | maintained | Aug 15, 2023 |
| sandy draper Guggenheim | Buy | $10.0 | maintained | Aug 10, 2023 |
| mark mahaney Evercore ISI | Hold | $10.0 | maintained | Aug 10, 2023 |
| jonathan yong Credit Suisse | Hold | $8.0 | maintained | Aug 9, 2023 |
| michael cherny Bank of America Securities | Buy | $8.0 | maintained | May 11, 2023 |
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.
When did it IPO
2020
Staff Count
952
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Market Cap
$2.61B
In 2023, GDRX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GDRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
JAMF-USD
$20.7
PDCO-USD
$28.35
BEAM-USD
$33.54
PLXS-USD
$95.43
DORM-USD
$82.82
MYRG-USD
$154.12
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
